Improving vaccine responses for influenza through glycosylation selection
Selecting HA glycosylation for improved vaccine responses
This study is looking at how changes in a part of the flu virus can help make vaccines work better, with the goal of creating a stronger vaccine that protects more people from different strains of the flu.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11086149 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of influenza vaccines by selecting specific glycosylation patterns on the hemagglutinin (HA) protein of the virus. The study aims to understand how variations in glycosylation can influence the immune response and the virus's ability to evade immunity. By investigating the glycosylation of HA, researchers hope to identify optimal structures that can lead to more effective vaccines against various strains of the influenza virus. This work is crucial for developing a universal influenza vaccine that can provide better protection for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of influenza infection, including those with weakened immune systems, the elderly, and healthcare workers.
Not a fit: Patients who are not at risk for influenza or those who have already received a vaccine that is effective against the current strains may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective influenza vaccines that provide broader and longer-lasting immunity.
How similar studies have performed: Previous research has shown promise in enhancing vaccine responses through glycosylation modifications, indicating that this approach could lead to significant advancements in vaccine development.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Zaia, Joseph — Boston University Medical Campus
- Study coordinator: Zaia, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.